Patents by Inventor Seong-Hyun Ho

Seong-Hyun Ho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210163575
    Abstract: The present disclosure relates to an expression vector that carries a polynucleotide coding for a coagulation factor VIII mutant and has increased protein expression and a pharmaceutical composition containing the expression vector for preventing or treating hemorrhagic disease or hemorrhage. The factor VIII mutant of the present disclosure is derived by deleting a part of the B-domain (residues 784-1667) and a part of the a3 region (residues 1668-1671) in factor VIII and, as a result, an expression vector carrying a polynucleotide coding for the factor VIII mutant has remarkably increased protein expression.
    Type: Application
    Filed: December 5, 2018
    Publication date: June 3, 2021
    Applicants: G&P BIOSCIENCE CO., LTD., REYON PHARMACEUTICAL CO., LTD.
    Inventors: Seong-Hyun HO, Su Jin PARK
  • Publication number: 20210113668
    Abstract: The present disclosure relates to a composition for increasing the expression of a growth factor gene, which contains core-shell structured microparticles as an active ingredient. When administered in vivo along with a growth factor gene, the composition for increasing the expression of a growth factor gene of the present disclosure can increase the expression of the co-administered gene by at least 30%. Especially, when administered along with at least one gene selected from a human hepatocyte growth factor (HGF) gene, an isoform gene of the human hepatocyte growth factor and a variant gene thereof, or at least one gene selected from a human insulin-like growth factor 1 (IGF1) gene, an isoform gene of the human insulin-like growth factor 1 and a variant gene thereof, which are appropriate for the present disclosure, the composition can increase the expression of the gene by at least 30%.
    Type: Application
    Filed: February 12, 2019
    Publication date: April 22, 2021
    Applicants: G&P BIOSCIENCE CO., LTD., REYON PHARMACEUTICAL CO., LTD.
    Inventors: Seong-Hyun HO, Su Jin PARK
  • Publication number: 20210113480
    Abstract: The present disclosure relates to a composition for increasing the expression of a blood coagulation factor gene, which contains core-shell structured microparticles as an active ingredient. When administered in vivo along with blood coagulation factor VIII gene or a variant gene thereof, the composition for increasing the expression of a blood coagulation factor gene of the present disclosure can increase the expression of the gene by at least 30%. When administered along with a gene therapeutic agent, the composition can achieve a therapeutic effect even with a very small amount of a gene, and thus is useful.
    Type: Application
    Filed: February 12, 2019
    Publication date: April 22, 2021
    Applicants: G&P BIOSCIENCE CO., LTD., REYON PHARMCEUTICAL CO., LTD.
    Inventors: Seong-Hyun HO, Su Jin PARK
  • Patent number: 8716446
    Abstract: The present invention provides for biopolymer conjugates of an IL-11 analog (mIL-11) and a biocompatible polymer. The mIL-11 of the invention displays an enhanced resistance to acidolysis and shows increased stability as compared to rhIL-11. The conjugates of the present invention are characterized by a longer serum half-life and exhibit essentially no loss of activity as compared to the corresponding unconjugated mIL-11.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: May 6, 2014
    Assignees: Biopolymed Inc., Viromed Co., Ltd.
    Inventors: Yuni Jung, Seong-Hyun Ho, Myung-Ok Park, Myoung-Suk Kim
  • Publication number: 20100098658
    Abstract: The present invention provides for biopolymer conjugates of an IL-11 analog (mIL-11) and a biocompatible polymer. The mIL-11 of the invention displays an enhanced resistance to acidolysis and shows increased stability as compared to rhIL-11. The conjugates of the present invention are characterized by a longer serum half-life and exhibit essentially no loss of activity as compared to the corresponding unconjugated mIL-11.
    Type: Application
    Filed: August 21, 2009
    Publication date: April 22, 2010
    Inventors: Yuni JUNG, Seong-Hyun Ho, Myung-Ok Park, Myoung-Suk Kim
  • Patent number: 7175840
    Abstract: The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such as angiostatin or parts thereof, and transplanting the recombinant vector or a cell that is transfected or transduced with the recombinant vector into the affected area of a patient, and also provides the compositions for the gene therapy. The compositions for the gene therapy according to the present invention can be used effectively for the treatment of rheumatoid arthritis, for which effective treating methods have not been developed until now, by providing the anti-angiogenic proteins into the knee of a patient continuously to prevent the synovial tissue hyperplasia and the resulting inflammation.
    Type: Grant
    Filed: January 3, 2002
    Date of Patent: February 13, 2007
    Assignee: Viromed Co., Ltd.
    Inventors: Jong-Mook Kim, Seong-Hyun Ho, Eun-Jin Park, Sunyoung Kim
  • Publication number: 20060198826
    Abstract: The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such as endostatin or parts thereof, and transplanting the recombinant vector or a cell that is transfected or transduced with the recombinant vector into the affected area of a patient, and also provides the compositions for the gene therapy. The compositions for the gene therapy according to the present invention can be used effectively for the treatment of rheumatoid arthritis, for which effective treating methods have not been developed until now, by providing the anti-angiogenic proteins into the knee of a patient continuously to prevent the synovial tissue hyperplasia and the resulting inflammation.
    Type: Application
    Filed: May 11, 2006
    Publication date: September 7, 2006
    Applicant: ViroMed Co., Ltd.
    Inventors: Jong-Mook Kim, Seong-Hyun Ho, Eun-Jin Park, Sunyoung Kim
  • Publication number: 20060193833
    Abstract: The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such as platelet factor-4 or parts thereof, and transplanting the recombinant vector or a cell that is transfected or transduced with the recombinant vector into the affected area of a patient, and also provides the compositions for the gene therapy. The compositions for the gene therapy according to the present invention can be used effectively for the treatment of rheumatoid arthritis, for which effective treating methods have not been developed until now, by providing the anti-angiogenic proteins into the knee of a patient continuously to prevent the synovial tissue hyperplasia and the resulting inflammation.
    Type: Application
    Filed: May 11, 2006
    Publication date: August 31, 2006
    Applicant: ViroMed Co., Ltd.
    Inventors: Jong-Mook Kim, Seong-Hyun Ho, Eun-Jin Park, Sunyoung Kim
  • Publication number: 20050277603
    Abstract: The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such as angiostatin or parts thereof, and transplanting the recombinant vector or a cell that is transfected or transduced with the recombinant vector into the affected area of a patient, and also provides the compositions for the gene therapy. The compositions for the gene therapy according to the present invention can be used effectively for the treatment of rheumatoid arthritis, for which effective treating methods have not been developed until now, by providing the anti-angiogenic proteins into the knee of a patient continuously to prevent the synovial tissue hyperplasia and the resulting inflammation.
    Type: Application
    Filed: January 3, 2002
    Publication date: December 15, 2005
    Inventors: Jong-Mook Kim, Seong-Hyun Ho, Eun-Jin Park, Sunyoung Kim
  • Publication number: 20040082533
    Abstract: The electroporation-mediated delivery of plasmid containing cDNA for soluble p75 TNF (tumor necrosis factor) receptor linked to the Fc portion of human IgG1 (sTNFR:Fc) can be effectively used for the treatment of arthritis in a mammal.
    Type: Application
    Filed: August 8, 2003
    Publication date: April 29, 2004
    Inventors: Jong-Mook Kim, Seong-Hyun Ho, Woong Hahn, Seung-Shin Yu, Sunyoung Kim
  • Publication number: 20030130223
    Abstract: An intramuscular injection composition for treating arthritis in a mammal, which comprises a DNA encoding interleukin-1 receptor antagonist (IL-1Ra) and pharmaceutically acceptable carriers
    Type: Application
    Filed: December 27, 2002
    Publication date: July 10, 2003
    Inventors: Jong-Mook Kim, Seong-Hyun Ho, Woong Hahn, Sunyoung Kim